The short version of receptor agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Water and aqueous buffers | Near neutral pH |
| Storage temperature | Minus 20 to minus 80 C | Long-term, lyophilized |
| Analytical method | RP-HPLC | Purity assessment |
| Typical purity | Greater than 95 percent | Research-grade material |
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Carbonate is found frequently in geologic settings and constitutes an enormous carbon reservoir. Calcium carbonate occurs as aragonite, calcite and dolomite as significant constituents of the calcium cycle. The carbonate minerals form the rock types: limestone, chalk, marble, travertine, tufa, and others.
=== Saliva tests === In 2008, scientists announced that the more cost effective saliva testing could eventually replace some blood tests, as saliva contains 20% of the proteins found in blood. Saliva testing may not be appropriate or available for all markers. For example, lipid levels cannot be measured with saliva testing.
Chemical hazard data in the dashboard comes from both traditional laboratory animal studies and high-throughput screening. Biological data from high-throughput screening is generated by EPA's ToxCast program, the ToxCast data in the database provides information about the assays used and their response potency and efficacy. These data can be found in the bioactivity tab. The Chemicals Dashboard can be accessed via a web interface or sets of data within it can be downloaded for use offline. The Lists tab can be used to browse and download groups of related chemicals based on their relevance to a specific research topic (such as additives in cigarettes or chemicals demonstrating effects on neurodevelopmental effects) or the specific assay endpoints they are covered by. Within the online dashboard searches can be performed by product/use categories, assay/gene, systematic name, synonym, CAS number, DSSTox Substance ID or InChiKey. Under the Advanced Search tab chemicals can be searched based on their mass or molecular formula. Searches can also be performed for groups of chemicals based on Chemical Name CASRN, InChIKey, DSSTox Substance ID, DSSTox Compound ID, InChIKey Skeleton, MS-Ready Formula, Exact Formula, or Monoisotopic Mass using the batch search function.
Sources: en.wikipedia.org
The National Institutes of Health (NIH) is the primary agency of the United States federal government responsible for biomedical and public health research. It was founded in 1887 and is part of the United States Department of Health and Human Services (HHS). Many NIH facilities are located in Bethesda, Maryland, and other nearby suburbs of the Washington metropolitan area, with other primary facilities in Research Triangle Park in North Carolina and smaller satellite facilities located around the United States. The NIH conducts its scientific research through the NIH Intramural Research Program (IRP) and provides significant biomedical research funding to non-NIH research facilities through its Extramural Research Program. As of 2013, the IRP had 1,200 principal investigators and more than 4,000 postdoctoral fellows in basic, translational, and clinical research, being the largest biomedical research institution in the world, while, as of 2003, the extramural arm provided 28% of biomedical research funding spent annually in the U.S., or about US$26.4 billion. Basic research by the NIH contributed to every new drug approved by the Federal Drug Administration over the period 2010–2016. In early 2025, the Trump administration froze key NIH operations, and by January 2026 about 2,600 grants totaling $1.4 billion remained suspended, though some were reinstated due to court orders.
Enzymes are crucial to metabolism because they allow organisms to drive reactions that require energy and will not occur by themselves, by coupling them to spontaneous reactions that release energy. Enzymes act as catalysts—they allow a reaction to proceed more rapidly—and they also allow the regulation of the rate of a metabolic reaction, for example, in response to changes in the cell's environment or to signals from other cells. The metabolic system of a particular organism determines which substances it will find nutritious and which poisonous. For example, some prokaryotes use hydrogen sulfide (H₂S) as a nutrient, yet this gas is poisonous to some animals. Since hydrogen sulfide is a gasotransmitter, certain mammals including humans produce H₂S naturally in very small concentrations where it serves vital signaling and regulatory functions. The basal metabolic rate of an organism is the measure of the amount of energy consumed by all of these chemical reactions. A notable feature of metabolism is the similarity of the basic metabolic pathways among vastly different species. For example, the set of carboxylic acids that are best known as the intermediates in the citric acid cycle are present in all known organisms, being found in species as diverse as the unicellular bacterium Escherichia coli (E. coli) and huge multicellular organisms like elephants. These similarities in metabolic pathways are likely due to their early appearance in evolutionary history, and their retention is likely due to their efficacy.
Fibrous papules are also termed facial angiofibromas and were formerly and incorrectly termed adenoma sebaceum (fibrous papules are unrelated to sebaceous glands). They develop in up to 8% of the general adult population and occur as 1 to 3 pink to red, dome-shaped papules in the central areas of the face, nose, and/or lips. About 75% of individuals with tuberous sclerosis present with fibrous papules in their infancy or early childhood; when associated with this rare disease, the lesions often occur as multiple papules in symmetrical, butterfly-shaped patterns over both cheeks and the nose. Fibrous papules also occur in individuals with multiple endocrine neoplasia type 1 (a study done in Japan found that 43% of individuals with this genetic disease bore facial angiofibromas) and, uncommonly, in individuals with Birt-Hogg-Dube syndrome.
== Frequency == Birth defects with symptoms related to CLSD are estimated to affect one in every 500 to 1,000 babies in the United States of America Recommended that CLSD is evaluated in all patients with late-closing fontanels and hypertelorism Recent case found in a caucasian male with a SEC23 inherited mutation from the father combined with another unknown mutation that leads to the symptoms of CLSD despite a healthy gene inherited from the mother Measurement of parental and patient endoplasmic reticulums show distention in both the father and the child, but not the mother as compared to a control measurement. The child was significantly more distended than the father and the mother. Frequency of the disorder may be greater than once thought, and may be linked more closely to all cases of late-closing fontanels and hypertelorism
Sources: en.wikipedia.org
The two got official approval from Valve to release Sven Co-op on Steam as a standalone title in 2012, though opted to wait nearly a year to announce this in July 2013 to give their team time to develop a hotfix for the current version of the mod. This standalone title was released on January 22, 2016, and includes all the assets for Half-Life required to play that game without installing the original game; players are still required to have purchased and installed Opposing Force and Blue Shift to play those in the standalone release of Sven Co-op. The standalone version includes updated versions of the Half-Life campaign maps, improved versions of popular maps developed for Sven Co-op, and additional scripting tools that will allow level designers to further customize new maps beyond the default GoldSrc. McDermott stated that their team anticipates continuing to improve tools for level designers, such as being able to replace the game's default heads-up display, though as the game is still developed in the team's free time, there is no information on when these will be available.
=== Prey === Rattlesnakes typically consume mice, rats, rabbits, ground squirrels, gophers, prairie dogs, ground-nesting birds and other small animals (such as lizards, frogs, toads and occasionally American mink and weasels). They lie in wait for their prey, or hunt for it in holes. The rattlesnake's defence and hunting mechanisms are bound to its physiology and its environment. More importantly environmental temperature can influence the ability of ectotherms. The prey is killed quickly with a venomous bite as opposed to constriction. If the bitten prey moves away before dying, the rattlesnake can follow it by its scent. When it locates the fallen prey, it checks for signs of life by prodding with its snout, flicking its tongue, and using its sense of smell. Once the prey has become incapacitated, the rattlesnake locates its head by odors emitted from the mouth. The prey is then ingested head first, which allows wings and limbs to fold at the joints in a manner that minimizes the girth of the meal. The gastric fluids of rattlesnakes are extremely powerful, allowing for the digestion of flesh and bone. Optimal digestion occurs when the snake maintains a body temperature between 80 and 85 °F (27 and 29 °C). If the prey is small, the rattlesnake often continues hunting. If the meal was adequate, the snake finds a warm, safe location in which to coil up and rest until the prey is digested. Feeding habits play an important ecological role by limiting the size of rodent populations, which prevents crop damage and stabilizes ecosystems.
=== Social policies: "Three Transformations" === Perhaps inspired by the Three Principles of the People, Liu Wenhui adopted a frontier policy known as the "Three Transformations" (san hua zhengce, 三化政策). Although described by Liu as a policy, it was closer to a loose model of governance. These three transformations included transformation through virtuous rule (de hua; 德化), transformation through assimilation (tong hua; 同化), and transformation through progress (jin hua; 進化). For Liu, virtuous rule was to win the hearts and minds of the non-Han populace, and progress would establish an interventionist, "fluid" government that avoided "static" stagnation under laissez-faire rule. However, Liu refrained from elucidating on the exact nature such progress would take. Liu also reportedly adopted different management styles for areas of Xikang depending on the ethnic group that inhabited them. For Tibetan areas, he advocated "steady progress" (稳进); for Han areas, "gradual progress" (逐进). Finally, for Yi areas, he called for "rapid progress" (猛进). These were called the "Three Advances" (三进主义). On the matter of ethnic policy, Liu's government was highly selective. Although his administration was relatively tolerant of Tibetans, even patronizing Tibetan Buddhism and establishing schools for Tibetan students, it was highly discriminatory against the Yi people, calling for the complete erasure of Yi identity. For many Han settlers in Xikang, the Yi were a "scourge", associated with violence and slave-raiding; the Yi, in turn, spoke of a "Han scourge".
Genetic research has produced several genetically modified varieties. 'New Leaf', owned by Monsanto Company, incorporates genes from Bacillus thuringiensis (source of most Bt toxins in transcrop use), which confers resistance to the Colorado potato beetle; 'New Leaf Plus' and 'New Leaf Y', approved by US regulatory agencies during the 1990s, also include resistance to viruses. McDonald's, Burger King, Frito-Lay, and Procter & Gamble announced they would not use genetically modified potatoes, and Monsanto published its intent to discontinue the line in March 2001. Potato starch contains two types of glucan, amylose and amylopectin, the latter of which is most industrially useful. Waxy potato varieties produce waxy potato starch, which is almost entirely amylopectin, with little or no amylose. BASF developed the 'Amflora' potato, which was modified to express antisense RNA to inactivate the gene for granule bound starch synthase, an enzyme which catalyzes the formation of amylose. 'Amflora' potatoes therefore produce starch consisting almost entirely of amylopectin, and are thus more useful for the starch industry. In 2010, the European Commission cleared the way for 'Amflora' to be grown in the European Union for industrial purposes only—not for food. Nevertheless, under EU rules, individual countries have the right to decide whether they will allow this potato to be grown on their territory. Commercial planting of 'Amflora' was expected in the Czech Republic and Germany in the spring of 2010, but due to lack of acceptance BASF in 2012 stopped selling the variety in Europe.
Slurry ice can boost by up to 200% the cooling efficiency of existing cooling or freezing brine systems without any major changes to the system (i.e. heat exchanger, pipes, valves), and reduce the amount of energy consumption used for pumping.
Sources: en.wikipedia.org
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.
Repeated temperature cycling can promote aggregation and peptide degradation. Dividing material into single-use aliquots limits this risk.
Mass spectrometry is commonly used to confirm molecular mass and detect structural modifications. It is often paired with chromatographic purity assessment.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.